AbbVie Inc. (NYSE:ABBV) – Leerink Swann issued their Q1 2018 EPS estimates for shares of AbbVie in a research note issued on Tuesday. Leerink Swann analyst G. Porges expects that the company will earn $1.56 per share for the quarter. Leerink Swann has a “Buy” rating and a $106.00 price objective on the stock. Leerink Swann also issued estimates for AbbVie’s Q4 2018 earnings at $1.89 EPS.

Other equities analysts have also recently issued research reports about the company. Societe Generale boosted their price target on AbbVie in a report on Tuesday, November 21st. Goldman Sachs Group reissued a “buy” rating and set a $100.00 price target (up previously from $85.00) on shares of AbbVie in a report on Friday, September 8th. Jefferies Group reissued a “buy” rating and set a $94.00 price target on shares of AbbVie in a report on Friday, September 8th. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $100.00 target price on shares of AbbVie in a report on Friday, September 15th. Finally, SunTrust Banks reaffirmed a “buy” rating and issued a $95.00 target price on shares of AbbVie in a report on Wednesday, September 13th. Seven investment analysts have rated the stock with a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $96.66.

AbbVie (ABBV) traded up $0.19 during trading on Wednesday, hitting $95.41. The stock had a trading volume of 5,552,900 shares, compared to its average volume of 6,125,012. The company has a debt-to-equity ratio of 5.08, a current ratio of 1.45 and a quick ratio of 1.32. AbbVie has a 12 month low of $58.80 and a 12 month high of $98.52. The firm has a market cap of $152,012.06, a PE ratio of 17.93, a P/E/G ratio of 1.34 and a beta of 1.52.

AbbVie (NYSE:ABBV) last released its earnings results on Friday, October 27th. The company reported $1.41 earnings per share for the quarter, beating analysts’ consensus estimates of $1.39 by $0.02. The firm had revenue of $7 billion during the quarter, compared to the consensus estimate of $7 billion. AbbVie had a return on equity of 153.80% and a net margin of 24.38%. The company’s revenue was up 8.8% compared to the same quarter last year. During the same period in the prior year, the company posted $1.21 EPS.

The company also recently declared a quarterly dividend, which will be paid on Thursday, February 15th. Shareholders of record on Friday, January 12th will be issued a $0.71 dividend. The ex-dividend date is Thursday, January 11th. This represents a $2.84 annualized dividend and a yield of 2.98%. This is a positive change from AbbVie’s previous quarterly dividend of $0.64. AbbVie’s dividend payout ratio is presently 62.29%.

In other AbbVie news, SVP Azita Saleki-Gerhardt sold 8,300 shares of the stock in a transaction that occurred on Monday, September 11th. The stock was sold at an average price of $85.02, for a total value of $705,666.00. Following the transaction, the senior vice president now owns 93,099 shares in the company, valued at $7,915,276.98. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, VP Robert A. Michael sold 6,699 shares of the stock in a transaction that occurred on Thursday, September 28th. The stock was sold at an average price of $88.00, for a total value of $589,512.00. Following the completion of the transaction, the vice president now owns 10,007 shares in the company, valued at approximately $880,616. The disclosure for this sale can be found here. In the last quarter, insiders sold 277,125 shares of company stock worth $25,891,756. Corporate insiders own 0.23% of the company’s stock.

Several institutional investors have recently modified their holdings of ABBV. Bristlecone Advisors LLC purchased a new stake in AbbVie in the third quarter worth $113,000. Acropolis Investment Management LLC purchased a new stake in AbbVie in the second quarter worth $106,000. Ffcm LLC increased its position in AbbVie by 167.2% in the second quarter. Ffcm LLC now owns 1,539 shares of the company’s stock worth $111,000 after buying an additional 963 shares during the last quarter. Hudock Capital Group LLC increased its position in AbbVie by 109.5% in the second quarter. Hudock Capital Group LLC now owns 1,542 shares of the company’s stock worth $111,000 after buying an additional 806 shares during the last quarter. Finally, Hershey Trust Co. purchased a new stake in AbbVie in the third quarter worth $139,000. 69.32% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: This piece was posted by American Banking News and is owned by of American Banking News. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of international trademark and copyright law. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2017/12/06/leerink-swann-weighs-in-on-abbvie-inc-s-q1-2018-earnings-abbv.html.

AbbVie Company Profile

AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.

Receive News & Ratings for AbbVie Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie Inc. and related companies with MarketBeat.com's FREE daily email newsletter.